Adenosinergic Protection of Dopaminergic and GABAergic Neurons against Mitochondrial Inhibition through Receptors Located in the Substantia Nigra and Striatum, Respectively
Open Access
- 26 November 2003
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 23 (34) , 10982-10987
Abstract
Mitochondrial dysfunction may contribute to dopaminergic (DAergic) cell death in Parkinson's disease and GABAergic cell death in Huntington's disease. In the present work, we tested whether blocking A1receptors could enhance the damage to DAergic and GABAergic neurons caused by mitochondrial inhibition, and whether blocking A2areceptors could protect against damage in this model. Animals received an intraperitoneal injection of 8-cyclopentyl-1,3-dipropylxanthine (CPX) (A1antagonist) or 3,7-dimethyl-1-propargylxanthine (DMPX) (A2aantagonist) 30 min before intrastriatal infusion of malonate (mitochondrial complex II inhibitor). Damage was assessed 1 week later by measuring striatal dopamine, tyrosine hydroxylase (TH), and GABA content. In mice and rats, malonate-induced depletion of striatal dopamine, TH, or GABA was potentiated by pretreatment with 1 mg/kg CPX and attenuated by pretreatment with 5 mg/kg DMPX. To determine the location of the A1and A2areceptors mediating these effects, CPX or DMPX was infused directly into the striatum or substantia nigra of rats 30 min before intrastriatal infusion of malonate. When infused into the striatum, CPX (20 ng) potentiated, whereas DMPX (50 ng) prevented malonate-induced GABA loss, but up to 100 ng of CPX or 500 ng of DMPX did not alter malonate-induced striatal dopamine loss. Intranigral infusion of CPX (100 ng) or DMPX (500 ng), however, did exacerbate and protect, respectively, against malonate-induced striatal dopamine loss. Thus, A1receptor blockade enhances and A2areceptor blockade protects against damage to DAergic and GABAergic neurons caused by mitochondrial inhibition. Interestingly, these effects are mediated by A1and A2areceptors located in the substantia nigra for DAergic neurons and in the striatum for GABAergic neurons.Keywords
This publication has 30 references indexed in Scilit:
- NMDA Receptors Modulate Dopamine Loss due to Energy Impairment in the Substantia Nigra but not StriatumExperimental Neurology, 2000
- Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acidAnnals of Neurology, 1999
- Presynaptic GABAB and adenosine A1 receptors regulate synaptic transmission to rat substantia nigra reticulata neuronesThe Journal of Physiology, 1997
- Age-Dependent Differences in Survival of Striatal Somatostatin–NPY–NADPH–Diaphorase-Containing Interneurons versus Striatal Projection Neurons after Intrastriatal Injection of Quinolinic Acid in RatsExperimental Neurology, 1997
- In Vivo Amino Acid Release From the Striatum of Aging Rats: Adenosine ModulationNeurobiology of Aging, 1997
- The mitochondrial inhibitor malonate enhances NMDA toxicity in the neonatal rat striatumDevelopmental Brain Research, 1995
- Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801Brain Research, 1995
- Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiographyNeuropharmacology, 1995
- Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor MalonateJournal of Neurochemistry, 1993
- Adenosinergic modulation of the EEG and locomotor effects of the A2 agonist, CGS 21680Pharmacology Biochemistry and Behavior, 1993